anticancer agent 15

Anticancer agent 15, an anticancer agent, exerts its efficacy by elevating intracellular levels of reactive oxygen species (ROS) and inducing cell death in melanoma cancer cells through necroptosis.

(S)-5-chloro-N-(1-((4-chlorophenyl)amino)-1-oxo-3-phenylpropan-2-yl)-2-hydroxybenzamide has antifungal and tuberculostatic activities.

Anticancer Agent 157 (compound 15) is a nitric oxide (NO) inhibitor with IC50 values of 0.62 μg/mL, exhibiting both anti-inflammatory and anticancer effects. It interacts with inducible NO synthase (iNOS) and caspase 8, which facilitates apoptosis through nuclear fragmentation and chromatin condensation. Additionally, Anticancer Agent 157 effectively inhibits HT29 colon cancer cells (IC50 =2.45 μg/mL), Hep-G2 liver cancer cells (IC50 =3.25 μg/mL), and B16-F10 murine melanoma cells (IC50 =3.84 μg/mL) [1].

Anticancer agent 154 (Compound 8h) enhances reactive oxygen species production, causes mitochondrial damage, and promotes cell apoptosis and DNA damage. It triggers ferroptosis by depleting GSH, diminishing GPX4 expression, and escalating lipid peroxidation. Additionally, it effectively suppresses the proliferation of various cancer cells (HT29, H1975, A549, and MCF-7) with IC50 values ranging from 1.0 to 1.9 μM [1].

Anticancer Agent 153 (Compound 3) promotes apoptosis through the generation of Reactive Oxygen Species (ROS) and elevates the loss of Mitochondrial Membrane Potential (MMP), effectively inhibiting cancer cell proliferation [1].

Anticancer agent 158 (compound 7c) demonstrates potent efficacy against various cancer cell lines, with IC50 values of 7.93 μM for HepG-2, 9.28 μM for MDA-MB-231, and 13.28 μM for HCT-116; however, it exhibits reduced potency with an IC50 of 181.89 μM against an unspecified cell line [1].

Compound 156, also referred to as compound 11, is a potent miliusanes-based anticancer agent that demonstrates effective inhibition of human cancer cell growth and exhibits substantial cytotoxicity against gastric cancer cells [1].

Antiproliferative agent-15 is a reagent with anticancer activity. Antiproliferative agent-15 showed antiproliferative activity against human colon cancer (HCT116 and HCT15) and brain cancer (LN-229 and GBM-10).

ARN-21934 is a potent, highly selective, blood-brain barrier (BBB) penetrant inhibitor for human topoisomerase II α over β. It inhibits DNA relaxation with an IC50 of 2 μM, compared to 120 μM for Etoposide. ARN-21934 exhibits favorable in vivo pharmacokinetic properties and shows promise in anticancer research, displaying affinity for topoIIα with an IC50 of 2 μM and for topoIIβ with an IC50 of 120 μM. It demonstrates activity against human cancer cell lines including melanoma (A375: 12.6 μM, G-361: 8.1 μM), breast (MCF7: 15.8 μM), endometrial (HeLa: 38.2 μM), lung (A549: 17.1 μM), and prostate (DU145: 11.5 μM) cancer cells. Following a single intraperitoneal injection of 10 mg/kg, ARN-21934 achieves a peak plasma concentration of 0.68 μg/mL in 15 minutes, with a half-life of 149 minutes, and remains detectable in plasma and the brain for up to 360 minutes. [1] Jose Antonio Ortega, et al. Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β. J Med Chem. 2020 Nov 12;63(21):12873-12886.

Anticancer agent 109 (compound 6-15) acts as an inhibitor targeting the Gas6-Axl axis, demonstrating significant anti-cancer properties. This compound suppresses the expression of Gas6, Axl, p-PI3K, and p-AKT in cancer cells, thereby inducing G1 phase arrest and promoting apoptosis of cancer cells. Additionally, Anticancer agent 109 effectively inhibits tumor growth in nude mouse tumor-bearing models [1].

Compound 15 (Anticancer agent 119), an N-acylated ciprofloxacin derivative, exhibits antibacterial activity and induces the production of ROS, further promoting apoptosis in cancer cells [1].